A Phase 3 study of bimekizumab in participants with moderate to severe hidradenitis suppurativa reached primary completion on 22 July 2026, according to ClinicalTrials.gov. The completed trial enrolled 658 participants and was designed to evaluate the safety of long-term bimekizumab therapy.
Background
The study evaluated bimekizumab in people with moderate to severe hidradenitis suppurativa, a condition listed in the registry as the trial’s sole disease area. The data provided identify bimekizumab as the study intervention but do not provide its drug class, mechanism of action, prior approvals, or prevalence information.
Trial design
This was a Phase 3 study listed as completed in ClinicalTrials.gov. It enrolled 658 participants with moderate to severe hidradenitis suppurativa and evaluated bimekizumab as the intervention. The registry summary states that the purpose was to evaluate the safety of long-term therapy in study participants with the condition.
The supplied record does not list comparator arms, dosing information, or a primary outcome measurement. It also does not provide outcome analyses or participant-level results.
What this means
Primary completion marks the end of the trial’s planned primary data-collection period, while the registry status indicates that the study was completed. The available record supports a description of the study’s population, intervention, enrollment, and safety-focused purpose, but it does not establish efficacy, provide statistical findings, or support a new regulatory approval.
No adverse-event summary was included in the supplied data. As a result, the available information does not quantify adverse events or allow a conclusion about the long-term safety profile of bimekizumab in hidradenitis suppurativa.
Source
Source: ClinicalTrials.gov, trial record for NCT04901195, with the primary-completion event dated 22 July 2026. The registry record is available at clinicaltrials.gov/study/NCT04901195.